The development of antibody blockade of immune checkpoint regulators such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the program death-1 and its ligand (PD-1/PD-L1) axis has revolutionized cancer immunotherapy [117]. The gene discussed is CTLA4; the disease is cancer.